Image

Asia-Pacific Adenomyosis Drugs Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • May 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 455
  • No of Figures: 45

Asia-Pacific Adenomyosis Drugs Market, By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others),  Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others),  Patient Type (Adult, Geriatric, and Adolescence), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)- Industry Trends and Forecast to 2029.

Asia-Pacific Adenomyosis Drugs Market

Market Analysis and Insights

Adenomyosis is a benign uterine disorder in which endometrial glands and stroma are pathologically demonstrated in the myometrium. Women affected by adenomyosis may present with abnormal uterine bleeding (AUB), dysmenorrhea, dyspareunia, or infertility, but one-third of them are asymptomatic. Over the years, adenomyosis has remained a histopathological diagnosis made after hysterectomy in perimenopausal women with heavy menstrual bleeding (HMB) or pelvic pain. However, adenomyosis has also become a condition identified in young fertile-age women over the last decade because of the recent advancements in imaging techniques, even though a shared definition and classification are still lacking. Despite the improvement of diagnostic tools, the awareness of the condition is still poor.

The drugs used for the treatment of adenomyosis generally include anti-inflammatory drugs and hormonal drugs such as gonadotropin-releasing hormone analogs (Gnrh Analogs), estrogen-progestin, selective progesterone receptor modulators (SPRMs) or progestin, aromatase inhibitors, and gonadotropin-releasing hormone antagonist, among others. Some of these drugs are used to reduce adenomyotic lesion size and improve the patient's dysmenorrhea and quality of life.

The demand for adenomyosis drugs has increased more in developed countries. These countries had reimbursement policies for treatment along with the high prevalence of the disease and increasing healthcare expenditure. The market will grow in the forecasted period due to the exploration of emerging markets and increasing support of private and government agencies for treatment. 

Asia-Pacific adenomyosis drugs market report provides details of market share, new developments, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. Strategic initiatives such as collaboration, agreement, and signing of sales agreements to invent and innovate pharmacological treatments are the major drivers which are expected to propel the demand of the market in the forecast period.

Asia-Pacific adenomyosis drugs market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the Asia-Pacific adenomyosis drugs market will grow at a CAGR of 6.6% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Thousand, Pricing in USD

Segments Covered

By Type (Diffuse, Nodular, Sclerotic, Adult Cystic, and Others),  Treatment (Hormone Medication, Anti-Inflammatory Drugs, and Others),  Patient Type (Adult, Geriatric, and Adolescence ), Dosage Form (Parenteral, Oral, Others), End User (Hospitals, Clinics, Specialty Center, Home Healthcare, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)

Countries Covered

Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of the Asia-Pacific

Market Players Covered

Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others

 

Market Definition

Adenomyosis represents a unique pathophysiological condition in which normal-appearing endometrial mucosa resides within the myometrium and is thus protected from menstrual shedding. The resulting ectopic presence of endometrial tissue composed of glands and stroma is thought to affect normal contractile function and peristalsis of uterine smooth muscle, causing menometrorrhagia, infertility, and adverse obstetric outcomes. Adenomyosis imposes a substantial socioeconomic burden from increased medical care and loss of work productivity without mentioning the compromised quality of life.

Adenomyosis has a negative impact on women's quality of life in a high percentage of cases because of abnormal uterine bleeding and pain requiring a lifelong management plan through medical or surgical treatment. The choice depends on the woman's age, reproductive status, and clinical symptoms. However, the disease is increasingly diagnosed in young women with reproductive desire, and conservative treatments are preferred, such as hormonal medications.

Asia-Pacific Adenomyosis Drugs Market Dynamics

Drivers

  • High prevalence of adenomyosis disorders

Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, endometriosis, adenomyosis, abnormal vaginal bleeding, and breast pain and lumps, among others. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.

With the increasing women population worldwide, the target population for female reproductive disorder has also increased. Adenomyosis, a gynecologic condition characterized by the presence of endometrial glands and stroma within the myometrium, can significantly reduce the lifestyle of an individual. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women.

  • Advancement in the diagnosis of adenomyosis

The development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women also undergoing conservative treatments, identifying different phenotypes of the disease. After some attempts of histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium: intrinsic, extrinsic, intramural, and indeterminate. 

Opportunity

  • Increase demand for disease-specific drug treatment

According to pathogenic mechanisms, several medical hormonal and non-hormonal treatments are used off-label to manage pain and bleeding and to improve fertility outcomes. The use of GnRHa is indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis, and the highest pregnancy rate is reported in those undergoing frozen embryo transfer after GnRHa pre-treatment. In contrast, the use of GnRHa for pain and bleeding should be considered only for short-term treatment because of menopausal effects. The levonorgestrel-releasing intrauterine system (LNG-IUS) is also an effective, reversible, and long-term treatment used successfully to treat adenomyosis. Results show that it reduces menstrual bleeding, pain, and uterine volume and has an overall satisfaction of 72%. However, new drugs, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelet therapy, are under development for the treatment of adenomyosis.

Restraints/Challenges

The diagnostic tests for adenomyosis include highly technologically advanced products. The development of those products involves rigorous research and development by the developing player. Thus, the cost of the product remains high, which proportionally increases the cost of testing. The diagnostic tools and techniques used for the diagnosis of adenomyosis include ovarian endometrioma, adhesions, and deep nodular forms of the disease that often require ultrasonography or magnetic resonance imaging (MRI) to detect. Histologic verification, usually following surgical/laparoscopic visualization, can be useful in confirming the diagnosis, particularly for the most common superficial lesions.

The therapy of adenomyosis involves different stages and different procedures of treatment. Adenomyosis may be treated with surgery, hormonal drugs, anti-inflammatory drugs, etc. The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients, especially those who are asymptomatic but have a strong desire to preserve their uterus. Herbal drugs and home remedies are used as alternative therapies for the treatment of adenomyosis.

Recent Developments

  • In October 2021, Debiopharm, a Swiss-based, Asia-Pacific biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly adenomyosis, and its related diseases
  • In September 2019, Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million (AUD 3.05 Million) grant to determine the cause of adenomyosis and the physiological processes associated with the diseases

Asia-Pacific Adenomyosis Drugs Market Divide

Asia-Pacific adenomyosis drugs market is categorized into six notable segments which are based on type, treatment, patient type, dosage form, distribution channel and end user . The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Diffuse
  • Nodular
  • Sclerotic
  • Adult cystic
  • Others

On the basis of type, the Asia-Pacific adenomyosis drugs market is segmented into diffuse, nodular, sclerotic, adult cystic, and others.

Treatment

  • Hormone medications
  • Anti-inflammatory drugs
  • Others

On the basis of treatment, the Asia-Pacific adenomyosis drugs market is segmented into hormone medications, anti-inflammatory drugs, and others.

Patient Type

  • Adolescence
  • Adult
  • Geriatric

On the basis of patient type, the Asia-Pacific adenomyosis drugs market is segmented into adolescence,

adult, and geriatric.

Dosage Form

  • Parenteral
  • Oral
  • Others

On the basis of dosage form, the Asia-Pacific adenomyosis drugs market is segmented into parenteral, oral and others.

End User

  • Hospitals
  • Clinics
  • Specialty center
  • Home healthcare
  • Ambulatory centers
  • Others

On the basis of end user, the Asia-Pacific adenomyosis drugs market is segmented into hospitals, clinics, specialty center, home healthcare, ambulatory centers, and others.  

Distribution Channel

  • Hospital pharmacy 
  • Retail pharmacy
  • Online pharmacy
  • Others

On the basis of distribution channel, the Asia-Pacific adenomyosis drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.

Asia-Pacific Adenomyosis Drugs Market Regional Analysis/Insights

Asia-Pacific adenomyosis drugs market is analyzed, and market size insights and trends are provided by type, treatment, patient type, dosage form, distribution channel, and end user, as referenced above.

The regions covered in the Asia-Pacific adenomyosis drugs market report are Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of the Asia-Pacific.  

Japan is expected to dominate the Asia-Pacific market during the forecast period due to the increased incidence and diagnosis of the disease.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Asia-Pacific Adenomyosis Drugs Market Share Analysis

Asia-Pacific adenomyosis drugs market competitive landscape provides details about the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on Asia-Pacific adenomyosis drugs market.

Some of the key players in the Asia-Pacific adenomyosis drugs market are Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Viatris Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific Vs. Regional and Vendor Share Analysis. Please request an analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands' understanding of the market for additional countries (ask for the list of countries), literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you with data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 ASIA PACIFIC ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 2 ASIA PACIFIC DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 3 ASIA PACIFIC DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 4 ASIA PACIFIC DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 5 ASIA PACIFIC NODULAR IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6 ASIA PACIFIC NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 7 ASIA PACIFIC NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 8 ASIA PACIFIC SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 9 ASIA PACIFIC SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 10 ASIA PACIFIC SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 11 ASIA PACIFIC ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 12 ASIA PACIFIC ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 13 ASIA PACIFIC ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 14 ASIA PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 15 ASIA PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 16 ASIA PACIFIC ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 17 ASIA PACIFIC ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 18 ASIA PACIFIC JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 19 ASIA PACIFIC JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 20 ASIA PACIFIC ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 21 ASIA PACIFIC HORMONE MEDICATION IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 22 ASIA PACIFIC HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 23 ASIA PACIFIC GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 24 ASIA PACIFIC ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 25 ASIA PACIFIC SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 26 ASIA PACIFIC AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 27 ASIA PACIFIC GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 28 ASIA PACIFIC SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 29 ASIA PACIFIC ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 30 ASIA PACIFIC ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 ASIA PACIFIC ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 32 ASIA PACIFIC NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 33 ASIA PACIFIC SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 34 ASIA PACIFIC PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 35 ASIA PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 ASIA PACIFIC ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 37 ASIA PACIFIC ADULT IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 38 ASIA PACIFIC GERIATRIC IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39 ASIA PACIFIC ADOLESCENCE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 ASIA PACIFIC ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 41 ASIA PACIFIC ORAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 ASIA PACIFIC ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 43 ASIA PACIFIC PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44 ASIA PACIFIC PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 45 ASIA PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 46 ASIA PACIFIC ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 47 ASIA PACIFIC HOSPITAL IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48 ASIA PACIFIC CLINICS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 49 ASIA PACIFIC SPECIALTY CENTER IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50 ASIA PACIFIC HOME HEALTHCARE IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 51 ASIA PACIFIC AMBULATORY CENTERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 52 ASIA PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 53 ASIA PACIFIC ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 54 ASIA PACIFIC HOSPITAL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 55 ASIA PACIFIC RETAIL PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 56 ASIA PACIFIC ONLINE PHARMACY IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 57 ASIA PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 64 ASIA-PACIFIC SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 76 ASIA-PACIFIC ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 78 ASIA-PACIFIC AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 79 ASIA-PACIFIC GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 80 ASIA-PACIFIC SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 81 ASIA-PACIFIC ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 82 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 83 ASIA-PACIFIC NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 84 ASIA-PACIFIC SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 85 ASIA-PACIFIC PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 86 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 87 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 88 ASIA-PACIFIC ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 89 ASIA-PACIFIC PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 90 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 91 ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 92 JAPAN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 93 JAPAN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 94 JAPAN DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 95 JAPAN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 96 JAPAN NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 97 JAPAN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 98 JAPAN SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 99 JAPAN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 100 JAPAN ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 101 JAPAN OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 102 JAPAN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 103 JAPAN ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 104 JAPAN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 105 JAPAN JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 106 JAPAN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 107 JAPAN HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 108 JAPAN GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 109 JAPAN ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 110 JAPAN SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 111 JAPAN AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 112 JAPAN GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 113 JAPAN SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 114 JAPAN ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 115 JAPAN ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 116 JAPAN NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 117 JAPAN SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 118 JAPAN PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 119 JAPAN ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 120 JAPAN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 121 JAPAN ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122 JAPAN PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123 JAPAN ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 124 JAPAN ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 125 CHINA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 126 CHINA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 127 CHINA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 128 CHINA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 129 CHINA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 130 CHINA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 131 CHINA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 132 CHINA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 133 CHINA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 134 CHINA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 135 CHINA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 136 CHINA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 137 CHINA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 138 CHINA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 139 CHINA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 140 CHINA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 141 CHINA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 142 CHINA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 143 CHINA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 144 CHINA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 145 CHINA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 146 CHINA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 147 CHINA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 148 CHINA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 149 CHINA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 150 CHINA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 151 CHINA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 152 CHINA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 153 CHINA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 154 CHINA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 155 CHINA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 156 CHINA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 157 CHINA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 158 INDIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 159 INDIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 160 INDIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 161 INDIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 162 INDIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 163 INDIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 164 INDIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 165 INDIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 166 INDIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 167 INDIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 168 INDIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 169 INDIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 170 INDIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 171 INDIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 172 INDIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 173 INDIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 174 INDIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 175 INDIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 176 INDIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 177 INDIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 178 INDIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 179 INDIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 180 INDIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 181 INDIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 182 INDIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 183 INDIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 184 INDIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 185 INDIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 186 INDIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 187 INDIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 188 INDIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 189 INDIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 190 INDIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 191 SOUTH KOREA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 192 SOUTH KOREA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 193 SOUTH KOREA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 194 SOUTH KOREA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 195 SOUTH KOREA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 196 SOUTH KOREA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 197 SOUTH KOREA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 198 SOUTH KOREA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 199 SOUTH KOREA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 200 SOUTH KOREA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 201 SOUTH KOREA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 202 SOUTH KOREA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 203 SOUTH KOREA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 204 SOUTH KOREA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 205 SOUTH KOREA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 206 SOUTH KOREA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 207 SOUTH KOREA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 208 SOUTH KOREA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 209 SOUTH KOREA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 210 SOUTH KOREA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 211 SOUTH KOREA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 212 SOUTH KOREA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 213 SOUTH KOREA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 214 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 215 SOUTH KOREA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 216 SOUTH KOREA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 217 SOUTH KOREA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 218 SOUTH KOREA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 219 SOUTH KOREA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 220 SOUTH KOREA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 221 SOUTH KOREA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 222 SOUTH KOREA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 223 SOUTH KOREA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 224 AUSTRALIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 225 AUSTRALIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 226 AUSTRALIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 227 AUSTRALIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 228 AUSTRALIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 229 AUSTRALIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 230 AUSTRALIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 231 AUSTRALIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 232 AUSTRALIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 233 AUSTRALIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 234 AUSTRALIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 235 AUSTRALIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 236 AUSTRALIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 237 AUSTRALIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 238 AUSTRALIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 239 AUSTRALIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 240 AUSTRALIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 241 AUSTRALIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 242 AUSTRALIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 243 AUSTRALIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 244 AUSTRALIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 245 AUSTRALIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 246 AUSTRALIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 247 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 248 AUSTRALIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 249 AUSTRALIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 250 AUSTRALIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 251 AUSTRALIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 252 AUSTRALIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253 AUSTRALIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 254 AUSTRALIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 255 AUSTRALIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 256 AUSTRALIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 257 SINGAPORE ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 258 SINGAPORE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 259 SINGAPORE DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 260 SINGAPORE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 261 SINGAPORE NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 262 SINGAPORE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 263 SINGAPORE SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 264 SINGAPORE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 265 SINGAPORE ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 266 SINGAPORE OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 267 SINGAPORE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 268 SINGAPORE ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 269 SINGAPORE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 270 SINGAPORE JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 271 SINGAPORE ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 272 SINGAPORE HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 273 SINGAPORE GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 274 SINGAPORE ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 275 SINGAPORE SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 276 SINGAPORE AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 277 SINGAPORE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 278 SINGAPORE SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 279 SINGAPORE ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 280 SINGAPORE ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 281 SINGAPORE NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 282 SINGAPORE SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 283 SINGAPORE PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 284 SINGAPORE ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 285 SINGAPORE ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 286 SINGAPORE ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 287 SINGAPORE PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 288 SINGAPORE ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 289 SINGAPORE ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 290 THAILAND ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 291 THAILAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 292 THAILAND DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 293 THAILAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 294 THAILAND NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 295 THAILAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 296 THAILAND SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 297 THAILAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 298 THAILAND ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 299 THAILAND OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 300 THAILAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 301 THAILAND ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 302 THAILAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 303 THAILAND JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 304 THAILAND ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 305 THAILAND HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 306 THAILAND GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 307 THAILAND ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 308 THAILAND SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 309 THAILAND AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 310 THAILAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 311 THAILAND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 312 THAILAND ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 313 THAILAND ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 314 THAILAND NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 315 THAILAND SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 316 THAILAND PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 317 THAILAND ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 318 THAILAND ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 319 THAILAND ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 320 THAILAND PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 321 THAILAND ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 322 THAILAND ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 323 INDONESIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 324 INDONESIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 325 INDONESIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 326 INDONESIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 327 INDONESIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 328 INDONESIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 329 INDONESIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 330 INDONESIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 331 INDONESIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 332 INDONESIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 333 INDONESIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 334 INDONESIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 335 INDONESIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 336 INDONESIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 337 INDONESIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 338 INDONESIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 339 INDONESIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 340 INDONESIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 341 INDONESIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 342 INDONESIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 343 INDONESIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 344 INDONESIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 345 INDONESIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 346 INDONESIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 347 INDONESIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 348 INDONESIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 349 INDONESIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 350 INDONESIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 351 INDONESIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 352 INDONESIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 353 INDONESIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 354 INDONESIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 355 INDONESIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 356 PHILIPPINES ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 357 PHILIPPINES DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 358 PHILIPPINES DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 359 PHILIPPINES NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 360 PHILIPPINES NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 361 PHILIPPINES SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 362 PHILIPPINES SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 363 PHILIPPINES ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 364 PHILIPPINES ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 365 PHILIPPINES OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 366 PHILIPPINES ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 367 PHILIPPINES ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 368 PHILIPPINES JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 369 PHILIPPINES JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 370 PHILIPPINES ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 371 PHILIPPINES HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 372 PHILIPPINES GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 373 PHILIPPINES ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 374 PHILIPPINES SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 375 PHILIPPINES AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 376 PHILIPPINES GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 377 PHILIPPINES SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 378 PHILIPPINES ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 379 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 380 PHILIPPINES NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 381 PHILIPPINES SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 382 PHILIPPINES PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 383 PHILIPPINES ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 384 PHILIPPINES ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 385 PHILIPPINES ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 386 PHILIPPINES PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 387 PHILIPPINES ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 388 PHILIPPINES ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 389 MALAYSIA ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 390 MALAYSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 391 MALAYSIA DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 392 MALAYSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 393 MALAYSIA NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 394 MALAYSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 395 MALAYSIA SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 396 MALAYSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 397 MALAYSIA ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 398 MALAYSIA OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 399 MALAYSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 400 MALAYSIA ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 401 MALAYSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 402 MALAYSIA JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 403 MALAYSIA ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 404 MALAYSIA HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 405 MALAYSIA GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 406 MALAYSIA ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 407 MALAYSIA SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 408 MALAYSIA AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 409 MALAYSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 410 MALAYSIA SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 411 MALAYSIA ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 412 MALAYSIA ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 413 MALAYSIA NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 414 MALAYSIA SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 415 MALAYSIA PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 416 MALAYSIA ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 417 MALAYSIA ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 418 MALAYSIA ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 419 MALAYSIA PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 420 MALAYSIA ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 421 MALAYSIA ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 422 VIETNAM ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 423 VIETNAM DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 424 VIETNAM DIFFUSE IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 425 VIETNAM NODULAR IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 426 VIETNAM NODULAR IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 427 VIETNAM SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 428 VIETNAM SCLEROTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 429 VIETNAM ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 430 VIETNAM ADULT CYSTIC IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 431 VIETNAM OTHERS IN ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 432 VIETNAM ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 433 VIETNAM ATYPICAL POLYPOID ADENOMYOMAS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 434 VIETNAM JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY SYMPTOMS, 2020-2029 (USD THOUSAND)

TABLE 435 VIETNAM JUVENILE CYSTIC ADENOMYOSIS IN ADENOMYOSIS DRUGS MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 436 VIETNAM ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 437 VIETNAM HORMONE MEDICATIONS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 438 VIETNAM GONADOTROPIN-RELEASING HORMONE AGONISTS (GNRH AGONISTS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 439 VIETNAM ESTROGEN-PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 440 VIETNAM SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMS) OR PROGESTIN IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 441 VIETNAM AROMATASE INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 442 VIETNAM GONADOTROPIN-RELEASING HORMONE ANTAGONIST ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 443 VIETNAM SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 444 VIETNAM ANDROGEN DERIVATIVES IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 445 VIETNAM ANTI-INFLAMMATORY DRUGS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 446 VIETNAM NON-SELECTIVE NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 447 VIETNAM SELECTIVE COX-2 NSAIDS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 448 VIETNAM PREFERENTIAL COX-2 INHIBITORS IN ADENOMYOSIS DRUGS MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 449 VIETNAM ADENOMYOSIS DRUGS MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 450 VIETNAM ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 451 VIETNAM ORAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 452 VIETNAM PARENTERAL IN ADENOMYOSIS DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 453 VIETNAM ADENOMYOSIS DRUGS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 454 VIETNAM ADENOMYOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 455 REST OF ASIA-PACIFIC ADENOMYOSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Asia-Pacific Adenomyosis Drugs Market will grow at a CAGR of 6.6% during the forecast by 2029.
The diagnosis of adenomyosis is difficult, and this subsequently results in difficulty in the management of these patients are poised to restrict the Asia-Pacific Adenomyosis Drugs Market growth.
The major players operating in the Asia-Pacific Adenomyosis Drugs Market are Mayne Pharma Group Limited, Accord Healthcare, Boehringer Ingelheim International GmbH, Ferring B.V., Par Pharmaceutical (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc., Novartis AG, Amneal Pharmaceuticals LLC, Johnson & Johnson Services, Inc., Sanofi, Dr. Reddy's Laboratories Ltd., among others.
The major countries covered in the Asia-Pacific Adenomyosis Drugs Market are Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of the Asia-Pacific.